Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice

Journal of Neurology

Volumn 257, Issue 2, 2010, Pages 207-211

  Outteryck, Olivier ^a   Ongagna, J C ^b   Zephir H ^a   Fleury, M C ^b   Lacour, A ^a   Blanc, F ^b   Vermersch, P ^a   De Seze J ^b  

^a UNIV LILLE   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cohort analysis; France; Multiple sclerosis; Natalizumab; Safety; Treatment efficacy

Indexed keywords

NATALIZUMAB;

ADULT; ANTIBODY PRODUCTION; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL PLEURISY; BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FRANCE; HEADACHE; HUMAN; HYPEREOSINOPHILIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PRURITUS; RECURRENCE RISK; RELAPSE; SKIN ALLERGY; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA;

EID: 77949262359     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5294-0     Document Type: Article

References (14)

1. ® 300 mg (natalizumab) dans le traitement de la sclérose en plaques [PDF in French]. http://www.afssaps.fr/content/download/6205/60160/version/4/file/ mise-au-tysabri.pdf. Accessed 22 Mar 2009
2. Biogen Idec, Inc. TYSABRI update. http://www.biogenidec.com/site/tysabri- information-center.html. Accessed 26 Mar 2009
3. PA Calabresi G Giovannoni C Confavreux SL Galetta E Havrdova M Hutchinson L Kappos DH Miller PW O'Connor JT Phillips CH Polman EW Radue RA Rudick WH Stuart FD Lublin A Wajgt B Weinstock-Guttman DR Wynn F Lynn MA Panzara 2007 The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL Neurology 69 1391 1403 10.1212/01.wnl.0000277457.17420.b5 1:CAS:528:DC%2BD2sXhtVyntbzI 17761550 (Pubitemid 47511460)
4. C Confavreux S Vukusic 2006 Natural history of multiple sclerosis: a unifying concept Brain 129 606 616 10.1093/brain/awl007 16415308 (Pubitemid 43278223)
5. European Medicines Agency. TYSABRI European public assessment report: scientific discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/tysabri/H- 603-en6.pdf. Accessed 31 Mar 2009
6. HP Hartung 2009 New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab Lancet Neurol 8 28 30 10.1016/S1474-4422(08) 70281-3 19081511
7. FD Lublin SC Reingold 1996 Defining the clinical course of multiple sclerosis: results of an international survey Neurology 46 907 911 1:STN:280:DyaK28zntlOksg%3D%3D 8780061
8. GL Mancardi MP Amato R D'Alessandro F Drago C Milanese P Popoli L Provinciali P Rossi G Savettieri G Tedeschi M Rosaria Tola N Vanacore A Covezzoli M De Rosa C Piccinni N Montarano L Periotto A Addis N Martini 2008 Natalizumab: a country-based surveillance program Neurol Sci 29 Suppl 2 S235 S237 10.1007/s10072-008-0948-8 18690503
9. Munschauer F, Giovannoni G, Lublin F, O'Connor PW, Phillips JT, Polman CH, Pace A, Kim R, Panzara MA (2008) Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Poster 474 ACTRIMS/ECTRIMS 2008
10. AB Oturai N Koch-Henriksen T Petersen PEH Jensen F Sellebjerg PS Sorensen 2009 Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study Eur J Neurol 16 420 423 10.1111/j.1468-1331. 2008.02517.x 1:STN:280:DC%2BD1M3nsFCntw%3D%3D 19364368
11. CH Polman PW O'Connor E Havrdova M Hutchinson L Kappos DH Miller T Phillips FD Lublin G Giovannoni A Wajgt M Toal F Lynn MA Panzara AW Sandrock 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D 16510744 (Pubitemid 43313657)
12. CH Polman SC Reingold G Edan M Filippi HP Hartung L Kappos FD Lublin LM Metz HF McFarland PW O'Connor M Sandberg-Wollheim AJ Thompson BG Weinshenker JS Wolinsky 2005 Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria" Ann Neurol 58 840 846 10.1002/ana.20703 16283615 (Pubitemid 41746873)
13. N Putzki K Kollila S Woods E Igwe HC Diener V Limmroth 2009 Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis Eur J Neurol 16 424 426 10.1111/j.1468-1331.2008.02519.x 1:STN:280:DC%2BD1M3nsVekug%3D%3D 19187261
14. GA Schumacher G Beebe RF Kibler LT Kurland JF Kurtzke F McDowell 1965 Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis Ann NY Acad Sci 122 552 568